WO2005016276A3 - Ligand du recepteur sigma-1 presentant des proprietes d'inhibition de l'acetylcholinesterase - Google Patents

Ligand du recepteur sigma-1 presentant des proprietes d'inhibition de l'acetylcholinesterase Download PDF

Info

Publication number
WO2005016276A3
WO2005016276A3 PCT/US2004/025295 US2004025295W WO2005016276A3 WO 2005016276 A3 WO2005016276 A3 WO 2005016276A3 US 2004025295 W US2004025295 W US 2004025295W WO 2005016276 A3 WO2005016276 A3 WO 2005016276A3
Authority
WO
WIPO (PCT)
Prior art keywords
sigma
receptor
receptor ligand
inhibition properties
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/025295
Other languages
English (en)
Other versions
WO2005016276A2 (fr
Inventor
Vassilios Papadopoulos
Laurent Lecanu
Janet Greeson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Samaritan Pharmaceuticals Inc
Original Assignee
Georgetown University
Samaritan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University, Samaritan Pharmaceuticals Inc filed Critical Georgetown University
Priority to CA002534777A priority Critical patent/CA2534777A1/fr
Priority to EP04757425A priority patent/EP1651235A4/fr
Priority to AU2004264342A priority patent/AU2004264342A1/en
Priority to JP2006522719A priority patent/JP2007501254A/ja
Publication of WO2005016276A2 publication Critical patent/WO2005016276A2/fr
Publication of WO2005016276A3 publication Critical patent/WO2005016276A3/fr
Priority to US11/347,020 priority patent/US20060247248A1/en
Anticipated expiration legal-status Critical
Priority to US12/182,845 priority patent/US20090176802A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un nouveau composé et une nouvelle méthode permettant de prévenir ou de traiter des maladies neurodégénératives par inhibition de l'acétylcholinestérase et liaison du récepteur sigma-1. L'ester 2,3-bis-diméthylcarbamoyloxy-6-[4-(4-éthyl-piperazin-yl)-butyryl]-phényl d'acide diméthylcarbamique et ses dérivés représentent une nouvelle stratégie thérapeutique contre la neurotoxicité induite par le peptide amyloïde bêta, pour inhiber l'acétylcholinestérase, améliorer la transmission cholinergique, lier le récepteur sigma-1, et lilbérer un métabolite qui est actif à la fois en tant que récepteur sigma-1 et en tant qu'anti-oxydant.
PCT/US2004/025295 2003-08-05 2004-08-05 Ligand du recepteur sigma-1 presentant des proprietes d'inhibition de l'acetylcholinesterase Ceased WO2005016276A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002534777A CA2534777A1 (fr) 2003-08-05 2004-08-05 Ligand du recepteur sigma-1 presentant des proprietes d'inhibition de l'acetylcholinesterase
EP04757425A EP1651235A4 (fr) 2003-08-05 2004-08-05 Ligand du recepteur sigma-1 presentant des proprietes d'inhibition de l'acetylcholinesterase
AU2004264342A AU2004264342A1 (en) 2003-08-05 2004-08-05 Sigma-1 receptor ligand with acetylcholinesterase inhibition properties
JP2006522719A JP2007501254A (ja) 2003-08-05 2004-08-05 アセチルコリンエステラーゼ阻害特性を有する、シグマ‐１受容体配位子
US11/347,020 US20060247248A1 (en) 2003-08-05 2006-02-03 Sigma-1 receptor ligand with acetylcholinesterase
US12/182,845 US20090176802A1 (en) 2003-08-05 2008-07-30 Antidotes to exogenous neurotoxic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49276903P 2003-08-05 2003-08-05
US60/492,769 2003-08-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/347,020 Continuation-In-Part US20060247248A1 (en) 2003-08-05 2006-02-03 Sigma-1 receptor ligand with acetylcholinesterase

Publications (2)

Publication Number Publication Date
WO2005016276A2 WO2005016276A2 (fr) 2005-02-24
WO2005016276A3 true WO2005016276A3 (fr) 2005-07-07

Family

ID=34193147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/025295 Ceased WO2005016276A2 (fr) 2003-08-05 2004-08-05 Ligand du recepteur sigma-1 presentant des proprietes d'inhibition de l'acetylcholinesterase

Country Status (6)

Country Link
EP (1) EP1651235A4 (fr)
JP (1) JP2007501254A (fr)
CN (1) CN1863536A (fr)
AU (1) AU2004264342A1 (fr)
CA (1) CA2534777A1 (fr)
WO (1) WO2005016276A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060247248A1 (en) * 2003-08-05 2006-11-02 Vassilios Papadopoulos Sigma-1 receptor ligand with acetylcholinesterase
WO2010015040A1 (fr) * 2008-08-07 2010-02-11 Powmri Ltd Thérapie et prévention d'une protéinopathie tdp-43
CN103420941B (zh) * 2013-08-26 2015-09-23 浙江大学 2-甲氧基苯基-二甲胺基甲酸酯衍生物及制备和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072806A1 (en) * 2002-03-15 2004-04-15 Zhi-Xing Yao Neuroprotective spirostenol pharmaceutical compositions
WO2004108076A2 (fr) * 2003-06-02 2004-12-16 Samaritan Pharmaceuticals, Inc. Composes de benzamide anti-vih

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB846795A (en) * 1957-03-29 1960-08-31 Henri Morren New piperazine derivatives and process for the preparation thereof
US3284453A (en) * 1964-09-29 1966-11-08 American Cyanamid Co 4-(2-aroylethyl)-1-piperazinecarboxylic acid esters
FR2339401A1 (fr) * 1976-02-02 1977-08-26 Orsymonde N-phenacyl-piperazines
US5143910A (en) * 1989-09-07 1992-09-01 Shionogi & Co., Ltd. Piperaziniocephalosporins
CA2116117A1 (fr) * 1991-08-22 1993-03-04 Hiroyuki Sueoka Compose de type benzisoxazole et son utilisation
US6214994B1 (en) * 1997-04-21 2001-04-10 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1′-yl propanones
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
AU762726B2 (en) * 1998-03-31 2003-07-03 Acadia Pharmaceuticals, Inc. Compounds with activity on muscarinic receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072806A1 (en) * 2002-03-15 2004-04-15 Zhi-Xing Yao Neuroprotective spirostenol pharmaceutical compositions
WO2004108076A2 (fr) * 2003-06-02 2004-12-16 Samaritan Pharmaceuticals, Inc. Composes de benzamide anti-vih

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1651235A4 *

Also Published As

Publication number Publication date
AU2004264342A1 (en) 2005-02-24
JP2007501254A (ja) 2007-01-25
CN1863536A (zh) 2006-11-15
EP1651235A2 (fr) 2006-05-03
WO2005016276A2 (fr) 2005-02-24
CA2534777A1 (fr) 2005-02-24
EP1651235A4 (fr) 2008-12-17

Similar Documents

Publication Publication Date Title
WO2007106469A3 (fr) Derives bicycliques de l'acide carboxylique utiles dans le traitement de troubles metaboliques
WO2008097546A3 (fr) Composés inhibiteurs de cholinestérase
WO2001085093A3 (fr) Composes et methodes permettant la modulation de l'angiopathie cerebrale amyloide
WO2007129195A3 (fr) 4-pyrimidine-5-amino-pyrazoles
WO2007136759A3 (fr) Procédé de traitement et de prévention de troubles oculaires
WO2002009643A3 (fr) Vaccins pour protection a large spectre contre les maladies causees par neisseria meningitidis
WO2005060711A3 (fr) Procedes de traitement d'un trouble
WO2008011478A3 (fr) Procédés de traitement de douleur chronique utilisant des amides d'acide 3-aryl-3-hydroxy-2-amino-propioniques, amides d'acide 3-hétéroaryl-3-hydroxy-2-amino-propionique et composés connexes
WO2004091502A3 (fr) Composes d'acide benzoique 1,2,4-oxadiazole et utilisation de ceux-ci dans la suppression non-sens et le traitement de maladies
WO2005032493A3 (fr) Composes d'amides utilises en tant que ligands de canaux ioniques et utilisations correspondantes
WO2007094819A8 (fr) Dérivés de triazole modulant l'activité de hsp90
WO2008019395A3 (fr) Composés pour améliorer l'apprentissage et la mémoire
WO2007059230A3 (fr) 1h-benzimidazole-4-carboxamides substitues efficaces en tant qu’inhibiteurs de parp
TN2011000227A1 (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
WO2006039663A3 (fr) Methodes d'administration d'iloperidone
WO2001056573A8 (fr) Utilisation d'inhibiteurs de cox-2 en tant qu'agents procinetiques gastriques
WO2003092606A3 (fr) Inhibiteurs de cholinesterase pour prevenir les blessures causees par des produits chimiques
WO2009076602A8 (fr) 5-alkyl/alcényl-3-cyanopyridines en tant qu'inhibiteurs de kinase
WO2005092304A3 (fr) Agents antifongiques
WO2006093832A3 (fr) Derives d'amide en tant que ligands de canal ionique, compositions pharmaceutiques et methodes d'utilisation associees
WO2006081431A3 (fr) Composes utiles dans le traitement des maladies auto-immunes et des troubles de demyelinisation
WO2006088814A3 (fr) Forme posologique et procede de liberation soutenue d'un compose pyrazine substitue
WO2002036587A3 (fr) Composes heterocycliques azotes et procede de fabrication de ces composes et de leurs intermediaires
WO2005085236A3 (fr) Inhibiteurs de la caspase et leurs utilisations
WO2001041709A3 (fr) Methodes de traitement de maladie et d'inflammation liees a la mort de cellule

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480028827.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004264342

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006522719

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2534777

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11347020

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004264342

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004757425

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004757425

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11347020

Country of ref document: US